As of November 6, 2026, C4 Therapeutics, Inc. is a publicly traded company (Nasdaq: CCCC); its largest reported holder is Lynx1 Capital Management LP, with 9.99% on Schedule 13G/A of August 14, 2026, then Soleus Capital Master Fund, L.P. (9.99%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in C4 Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is C4 Therapeutics, Inc. a real, registered company?
- C4 Therapeutics, Inc. files with the SEC under CIK 1662579 (its SEC filings).
- Its shares are listed under the ticker CCCC on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Watertown, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under C4 Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Squadron Master Fund LP (filed 2026-08-14).
Who are C4 Therapeutics, Inc.'s owners and officers?
C4 Therapeutics, Inc.: incorporated in Delaware; business address in Watertown, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Squadron Master Fund LP | 6.9% |
| Schedule 13G/A, 2026-08-14 | Lynx1 Capital Management LP | 9.99% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-12 | Morgan Stanley | 8% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 6.9% |
| Schedule 13G, 2026-05-19 | Squadron Master Fund LP | 5% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 9.9% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 0.2% |
| Schedule 13G/A, 2026-04-22 | Wasatch Advisors LP | 4.7% |
| Schedule 13G/A, 2026-02-17 | Orbimed Capital LLC | 1% |
| Schedule 13G/A, 2026-02-17 | Lynx1 Capital Management LP | 7.3% |
| Schedule 13G/A, 2026-02-12 | Soleus Capital Master Fund, L.P. | 9.99% |
Questions about who owns C4 Therapeutics, Inc.
Who owns C4 Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of C4 Therapeutics, Inc.: Lynx1 Capital Management LP (9.99%, Schedule 13G/A, filed 2026-08-14), Soleus Capital Master Fund, L.P. (9.99%, Schedule 13G/A, filed 2026-02-12), Ra Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-05-15) and Morgan Stanley (8%, Schedule 13G/A, filed 2026-08-12); 2 more are listed above.
Who are the largest shareholders of C4 Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of C4 Therapeutics, Inc. on this page are Lynx1 Capital Management LP (9.99%), Soleus Capital Master Fund, L.P. (9.99%) and Ra Capital Management, L.P. (9.9%).
When did Lynx1 Capital Management LP buy into C4 Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G/A, filed 2026-02-17, reporting 7.3%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on C4 Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on C4 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on C4 Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own C4 Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,074,934 shares (0.82% of shares outstanding) (Form 4, 2026-02-18).
- , the chief financial officer: 382,323 shares (0.29% of shares outstanding) (Form 4, 2026-09-21).
- , the chief medical officer: 372,406 shares (0.28% of shares outstanding) (Form 4, 2026-07-13).
- , a director: 361,897 shares (0.28% of shares outstanding), 75,612 held directly and 286,285 indirectly (Form 4, 2026-10-02).
- , the chief scientific officer: 336,910 shares (0.26% of shares outstanding) (Form 4, 2026-02-18).
Shares outstanding: 131,317,488 as of 2026-10-30, from the company's latest SEC cover page.
How much has C4 Therapeutics, Inc. raised?
No fundraising or offering filing from C4 Therapeutics, Inc. is on file with us.
Keep reading
More on C4 Therapeutics, Inc. and the records around it.
C4 Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies: Xilio Therapeutics, Inc. (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), NextCure, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/c4-therapeutics